Industry News
Excerpt from the Press Release: SAN DIEGO, June 18, 2021 /PRNewswire/ –IRISYS, LLC, a San Diego-based provider of contract pharmaceutical development and manufacturing services, announced today that it has been issued U.S. Patent No. 11,033,530, Liposomal Anticancer Compositions. IRISYS scientists discovered a new way to deliver well-known anticancer therapeutics that may someday enable physicians to treat cancer patients…
Read More
Excerpt from the Press Release: DUBLIN and SOUTH SAN FRANCISCO, Calif., June 21, 2021 /PRNewswire/ — Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines, today announced top-line results from its Phase 2 study of 3 mg once-daily nezulcitinib compared to placebo,…
Read More
Excerpt from the Article: An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows. The findings have spurred investigators to open a clinical trial of the drug, novobiocin, for patients whose tumors carry the abnormality. In…
Read More
Excerpt from the Press Release: STUDY SHOWS GUARDANT REVEAL™ BLOOD-ONLY LIQUID BIOPSY TEST PREDICTS RISK FOR COLORECTAL CANCER RECURRENCE WITH INDUSTRY-LEADING SENSITIVITY For patients with early-stage colorectal cancer (CRC), the presence of circulating tumor DNA (ctDNA) or minimal residual disease (MRD) after curative intent treatment is becoming an important prognostic biomarker for cancer recurrence, and can…
Read More
Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, June 17, 2021 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the first patient has been dosed in a Phase II basket trial of taletrectinib…
Read More
Excerpt from the Press Release: TEL AVIV, Israel and BETHESDA, Maryland, June 17, 2021 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases. The announcement of the new research projects…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced that results from its Phase 1 first-in-human study of CX-2029 in patients with advanced…
Read More
Excerpt from the Press Release: WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced new preclinical data on its IRAKIMiD degrader KT-413’s potential as both a monotherapy and in combination with other anticancer…
Read More
Excerpt from the Press Release: WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, presented pre-clinical data for CFT7455, the Company’s lead program. CFT7455 is an orally bioavailable MonoDAC™ targeting IKZF1/3 for…
Read More
Excerpt from the Article: At the age of 43, and at the peak of her scientific career, Nadia Chaudhri received a terminal diagnosis in 2020 that altered the course of her life. “When I realized that being diagnosed with advanced ovarian cancer meant I would have to shut down my laboratory, I was devastated,” says the Department of…
Read More